Journal
OSTEOPOROSIS INTERNATIONAL
Volume 19, Issue 3, Pages 339-348Publisher
SPRINGER LONDON LTD
DOI: 10.1007/s00198-007-0462-5
Keywords
bone quality; bone turnover; collagen; fracture risk; matrix proteins
Categories
Ask authors/readers for more resources
Bone collagen maturation may be important for anti-fracture efficacy as the reduction in risk is only partly explained by a concomitant increase in BMD during anti-resorptive therapy. Different treatments caused diverse profiles in bone collagen degradation products, which may have implications for bone quality. Introduction The aim of the present study was to evaluate the effect of different anti-resorptive treatments on bone collagen maturation measured as the ratio between the degradation products of newly synthesized and mature isomerized C-telopeptides of type I collagen. Methods Participants were from cohorts of healthy postmenopausal women participating in double blind, placebo-controlled 2-year studies of alendronate, ibandronate, intranasal hormone replacement therapy (HRT), oral HRT, transdermal HRT, or raloxifene (n=427). The non-isomerized alpha alpha CTX and isomerized beta beta CTX were measured in urine samples obtained at baseline, and after 6, 12, and 24 months of therapy. Results Bone collagen maturation measured as the ratio between alpha alpha CTX and beta beta CTX showed that bisphosphonate treatment induced a collagen profile consistent with an older matrix with a 52% (alendronate) and 38% (ibandronate) reduction in the ratio between the two CTX isoforms vs. 3% and 15% with HRT or raloxifene, respectively. Conclusions Anti-resorptive treatments had different effects on the endogenous profile of bone collagen maturation. Whether that effect on bone collagen has an impact on bone strength independent on the treatment-dependent effect on BMD should be investigated.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available